NEWS

Photocure - full year report

Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
War on Cancer Nordics

The Economist & Oslo Cancer Cluster: War on Cancer Nordics

Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.

Oncoinvent closes $ 25 Million Private Placement

Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.

Targovax with full year report

Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.

Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway

Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).